PM
CYTK icon

Prosight Management’s Cytokinetics CYTK Stock Holding History

Prosight Management’s Portfolio CYTK Stock Details CYTK Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q4 		– Sell
-192,700
Closed -$10.2M – 39
2024
Q3 		$10.2M Sell
192,700
-37,300
-16% -$2.08M 2.5% 18
2024
Q2 		$12.5M Sell
230,000
-15,000
-6% -$905K 3.72% 9
2024
Q1 		$17.2M Buy
+245,000
New +$18.9M 4.78% 8

Other funds holding CYTK

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return

Prosight Management's CYTK Position: Q4 2024 in Review

Prosight Management sold out of Cytokinetics (CYTK) in Q4 2024, closing a stake of 192,700 shares — an estimated $10.2M sold.

Prosight Management first reported a position in CYTK in Q1 2024 and held it in 3 quarters. The position peaked at $17.2M in Q1 2024. 346 funds tracked by Wall St. Rank hold CYTK as of Q4 2024.

  • Prosight Management reported no remaining Cytokinetics position as of Q4 2024 after selling out during the quarter.
  • Prosight Management sold 192,700 Cytokinetics shares in Q4 2024, an estimated $10.2M.
  • Prosight Management first reported a position in Cytokinetics in Q1 2024 and held it in 3 quarters.
  • Prosight Management's Cytokinetics position peaked at $17.2M in Q1 2024.
  • 346 funds tracked by Wall St. Rank held Cytokinetics as of Q4 2024.

Based on Prosight Management's 13F filing for Q4 2024, filed 14 Feb 2025.